Who
Steven Ryder
Director
Company insider
Files Form 4 as: Director, MBX Biosciences; Chief Medical Officer, Rallybio; Director, Reata Pharmaceuticals.
In numbers
- Trades disclosed
- 24
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 7 Feb 2022
- Last trade
- 4 Jun 2026
- Last filed
- 5 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 5 Jun 2025filed 6 Jun 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 14 Feb 2025filed 19 Feb 2025 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 12 Sep 2024filed 13 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,963 at $0.00 | filing |
| 15 Feb 2024filed 16 Feb 2024 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,322 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,038 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —5,492 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —441 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —2,137 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticals | SEC FORM 4 Code D | —10,907 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $32K441 at $73.68 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —2,137 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Reata Pharmaceuticals | SEC FORM 4 Code A | $32K347 at $93.61 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Reata Pharmaceuticals | SEC FORM 4 Code A | $157K1,682 at $93.61 | filing |
| 6 Feb 2023filed 6 Feb 2023 | RLYB Rallybiooption or derivative · Biotechnology | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 11 Jul 2022filed 12 Jul 2022 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | $30K1,322 at $22.36 | filing |
| 11 Jul 2022filed 12 Jul 2022 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —6,038 at $0.00 | filing |
| 11 Jul 2022filed 12 Jul 2022 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —5,492 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.